BNET Industries
Last Fiscal Year Sales:$3.0M
- Public
- US
Dow Jones Description
Biopharmaceutical Mfr Focused on the Treatment of Coronary Artery Disease
Coo, Vice President & Chief Scientific Officer
John W. JacobsNumber of Employees 22
Peer Companies
NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414
News & Analysis
Filter by
cardiovascular biotherapeutics inc. - All News and Analysis
CardioVascular BioTherapeutics: The Wall Street Analyst Forum Presentation Transcript
Question-and-Answer SessionUnidentified Audience Member Question Inaudible Jack Jacobs You can't make a statistic correlation because, the way it worked is that not all the people who are tested -- you might want to repeat the question or --. Dan Montano Yeah, it wasn’t --...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| John W. Jacobs | Coo, Vice President & Chief Scientific Officer |
| Mickael Flaa | CFO & Vice President |
| Kenneth A Thomas | Vice President, R & D |
| Mike Norris | Vice President, Corp Development |
| William Jacobs | Vice President |
| John Jack | |
| Judy Pelton | Secretary |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Alexander G. Montano | Board of Directors |
| Gary B. Abromovitz | Board of Directors |
| Grant Gordon | Vice Chairman |
| Joong Ki Baik | Board of Directors |
| Robert Levin | Board of Directors |
| Thomas L. Ingram | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Cardiovascular BioTherapeutics, Inc. | Coo, Vice President & Chief Scientific Officer | Current |
| Cardiovascular BioTherapeutics, Inc. | Board of Directors | Current |
Mickael A. Flaa is a consultant who has served as our Vice President and Chief Financial Officer of Phage Biotechnology Corp. since June 2003. He devotes approximately 40% of his time to our business. He served as Interim Chief Financial Officer on a consulting basis for Breakaway Solutions, Inc., a public company, from February 2001 to 2002. From October 2000 to March 2002, Mr. Flaa served on the Board of Directors of UniCapital Corporation, a public company. From January 1999 to March 2000, he served as Chief Financial Officer and was a member of the Board of Directors for Sunbelt Integrated Trade Services, Inc. From May 1977 to January 1999, Mr. Flaa held various management positions with KPMG Peat Marwick LLP and in 1990 was elected to partnership. He is involved in the management and/or Board of Directors of Memson, Inc., Onnam Gaming, and Gestalt, LLC. Mr. Flaa received his undergraduate degree from Central Washington University.
| Organization | Position | Status |
|---|---|---|
| Phage Biotechnology Corporation | Chief Financial Officer | Current |
| Cardiovascular BioTherapeutics, Inc. | CFO & Vice President | Current |
| Cvbt | Director, Vice President, Chief Financial Officer | Current |
| Regenerative Medicine: Definitions | Director, Vice President, Chief Financial Officer | Current |
| Cardiovascular BioTherapeutics, Inc. | Board of Directors | Current |
| Breakaway Solutions | Interim Chief Financial Officer | Former |
| Unicapital Ltd. | Board of Directors | Former |
| Washington University | Undergraduate Degree | Former |
| Organization | Position | Status |
|---|---|---|
| Cardiovascular BioTherapeutics, Inc. | Vice President, R & D | Current |
| Regenerative Medicine: Definitions | Vice President, Research and Development | Current |
| Cvbt | Vice President Research | Current |
| Cvbt | Board of Directors | Current |
| Merck & Co. Inc. | Former | |
| Duke University | Ph.D In Biochemistry | Former |
| University of Delaware | Bachelor of Science Degree In Chemistry | Former |
| Organization | Position | Status |
|---|---|---|
| Cardiovascular BioTherapeutics, Inc. | Vice President, Corp Development | Current |
| Organization | Position | Status |
|---|---|---|
| Cardiovascular BioTherapeutics, Inc. | Vice President | Current |
| Cardiovascular BioTherapeutics, Inc. | Director, Operations | Former |
| Organization | Position | Status |
|---|---|---|
| Cardiovascular BioTherapeutics, Inc. | Current | |
| Cvbt | Former | |
| Merck & Co. Inc. | Former | |
| Washington University School of Medicine | Ph.D. in molecular biology | Former |
| Organization | Position | Status |
|---|---|---|
| Cardiovascular BioTherapeutics, Inc. | Secretary | Current |
| Organization | Position | Status |
|---|---|---|
| Cardiovascular BioTherapeutics, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Cardiovascular BioTherapeutics, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Cardiovascular BioTherapeutics, Inc. | Vice Chairman | Current |
| Cardiovascular BioTherapeutics, Inc. | Board of Directors | Former |
| Organization | Position | Status |
|---|---|---|
| Cardiovascular BioTherapeutics, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Cardiovascular BioTherapeutics, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Cardiovascular BioTherapeutics, Inc. | Board of Directors | Current |
Industry Transcripts by Seeking Alpha
-
Martek Biosciences Corporation F4Q09 (Qtr End 10/31/09) Earnings Call Transcript
on Dec 16, 2009about MATK
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes



